Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 51 entries
View as:

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Phase: N/A Priority: Normal
NCT ID: NCT01068782 Org: User:
Start: 04/30/10 End: 10/31/13 Due: 10/31/14

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Phase: N/A Priority: Normal
NCT ID: NCT01605227 Org: User:
Start: 07/31/12 End: 03/31/15 Due: 03/31/16

Study of XB010 in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06545331 Org: User:
Start: 08/06/24 End: 10/20/27 Due: 10/20/28

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Phase: N/A Priority: Normal
NCT ID: NCT04925284 Org: User:
Start: 06/07/21 End: 03/10/25 Due: 03/10/26

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06082167 Org: User:
Start: 06/07/24 End: 03/31/29 Due: 03/31/30

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03845166 Org: User:
Start: 03/20/19 End: 05/31/27 Due: 05/31/28

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT01761773 Org: User:
Start: 12/31/12 End: 07/31/14 Due: 07/31/15

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00796484 Org: User:
Start: 11/30/08 End: 11/30/10 Due: 11/30/11

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00704288 Org: User:
Start: 05/31/08 End: 12/31/12 Due: 12/31/13

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03690388 Org: User:
Start: 10/05/18 End: 12/31/24 Due: 12/31/25

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03170960 Org: User:
Start: 09/05/17 End: 08/31/24 Due: 08/31/25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00940225 Org: User:
Start: 09/30/09 End: 06/30/14 Due: 06/30/15

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01683110 Org: User:
Start: - End: - Due: -

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00215605 Org: User:
Start: 09/30/05 End: 07/31/12 Due: 07/31/13

A Safety Study of XL019 in Adults With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00522574 Org: User:
Start: 08/31/07 End: - Due: -

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01522443 Org: User:
Start: 03/31/12 End: 01/13/15 Due: 01/13/16

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Phase: N/A Priority: Normal
NCT ID: NCT01908426 Org: User:
Start: 09/26/13 End: 01/12/21 Due: 01/12/22

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01553656 Org: User:
Start: 02/28/11 End: 07/31/15 Due: 07/31/16

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Phase: N/A Priority: Normal
NCT ID: NCT04726332 Org: User:
Start: 02/10/21 End: 05/02/24 Due: 05/02/25

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06630247 Org: User:
Start: 10/17/24 End: 05/07/25 Due: 05/07/26

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00704392 Org: User:
Start: 06/30/08 End: 12/31/09 Due: 12/31/10

Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Phase: N/A Priority: Normal
NCT ID: NCT06962332 Org: User:
Start: 05/13/25 End: 04/30/26 Due: 04/30/27

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06943755 Org: User:
Start: 07/31/25 End: 06/30/29 Due: 06/30/30

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Phase: N/A Priority: Normal
NCT ID: NCT00595829 Org: User:
Start: 12/31/07 End: 02/28/09 Due: 02/28/10

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00526838 Org: User:
Start: 09/30/07 End: 12/31/10 Due: 12/31/11